Nuclear epidemiologic studies and the estimation of DREF.

Area of Science:

• Radiation epidemiology
• Public health
• Cancer risk assessment

Background:

• Estimating cancer risks from continuous radiation exposure using acute exposure data is a significant public health challenge.
• The dose and dose rate effectiveness factor (DDREF) is crucial for extrapolating acute exposure risks to chronic exposures.
• Previous recommendations, such as ICRP60, suggested a DDREF of 2, but some analyses indicate no difference between acute and chronic exposure risks.

Purpose of the Study:

• To analyze recent nuclear worker studies to estimate the DDREF for solid cancers.
• To evaluate the effectiveness of dose and dose rate in cancer risk estimation.

Main Methods:

• A meta-analysis was conducted on twelve mortality studies, each with at least 100 cancer deaths.
• The analysis compared the low dose rate (LDR) cancer effect to the high dose rate effect from the A-bomb survivor cohort (LSS).
• The ratio (Q) of LDR to high dose rate effects was calculated, with its reciprocal serving as the DDREF estimate.

Main Results:

• The meta-analysis yielded a Q value of 0.36, resulting in a DDREF estimate of 2.63 (95% CI: 1.61, 7.14).
• This estimate aligns more closely with a DDREF of 2 than 1, but is heavily influenced by two dissimilar studies (INWORKS and Mayak).
• Potential overestimation of cancer effects per dose in some studies, due to factors like neutron and internal emitter exposures before 1960, is noted.

Conclusions:

• The best estimate for the DDREF remains approximately 2.
• However, due to epidemiological study limitations, particularly dosimetry issues, a DDREF of 2 should be accepted with significant caution.
• The Mayak study is identified as the primary driver for the current DDREF estimate.